Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026
WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody for asthma and COPD
WIN027 is a long-acting bispecific targeting TSLP and IL-13 with best-in-disease efficacy potential
BASEL, Switzerland, May 04, 2026 (GLOBE NEWSWIRE) -- Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced an upsized $165M crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed. Proceeds will significantly extend the company's cash runway and enable multiple clinical readouts in the next 12 months.
Since launching in January 2025, Windward Bio has in-licensed 2 clinical-stage assets, raised $365M, and rapidly advanced both programs in the clinic.
WIN378, the lead program, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression of a wide array of immunological diseases. WIN378 ...
